Javier Ampuero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Javier Ampuero has a total of 885 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Romero-Gómez
UCM Digestive Diseases, Virgen del Rocio University Hospital, SeLiver Group, Institute of Biomedicine of Seville, Ciberehd, Department of Medicine, University of Seville, Seville, Spain
87 shared publications - Javier Crespo
Cantabria Cohort, Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain
19 shared publications - Rocío Gallego-Durán
Digestive Diseases Unit and CIBERehd, Virgen Del Rocío University Hospital, Seville, Spain
16 shared publications - José Luis Calleja
Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid, 28222 Madrid, Spain
13 shared publications Francisco Jorquera
Servicio de Aparato Digestivo, Complejo Asistencial Universitario de León, León, Spain
11 shared publicationsRocío Gallego-Durán
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain; SeLiver Group, Instituto de Biomedicina de Sevilla, Sevilla, Spain
11 shared publications
Latest Publications
- 31 July 2026
- Published by Wiley in Liver International
- Vol. 46 (9)
The REACT Score and the Evolving Phenotypes of Decompensated Cirrhosis
- 31 July 2026
- Published by Wiley in Liver International
- Vol. 46 (9)
The REACT Score and the Evolving Phenotypes of Decompensated Cirrhosis
- 22 June 2026
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 61 (9) , 1-10
Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis
Background Primary biliary cholangitis (PBC) is a liver disease frequently associated with extrahepatic manifestations. Although a relationship with kidney dysfunction has been reported, data about PBC and chronic kidney disease (CKD) are limited. We assessed the prevalence and incidence of CKD and identify associated risk factors in patients with PBC. Methods This was a multicenter retrospective study involving 1058 consecutive PBC patients. The presence of metabolic comorbidities, including diabetes, hypertension, and dyslipidemia was collected. CKD was defined as eGFR < 60 mL/min/1.73 m2. Results Baseline CKD was found in 10% of patients. The number of metabolic factors was associated with progressively lower eGFR levels and higher rates of CKD. Hypertension[OR 2.77 (95%CI 1.60–4.82)], diabetes[OR 2.17(95%CI 1.13–4.18)], ALT[OR 0.92(95%CI 0.88–0.96)], albumin[OR 0.24(95%CI 0.13–0.43)], and platelets[OR 0.996(95%CI 0.992–0.999)] were associated with baseline CKD. CKD was associated with higher mortality (32.1% vs. 7.3%). Seven percent of patients developed CKD. Baseline FIB-4 was associated with CKD incidence: < 1.45: 3% (13/428), 1.45–3.25: 10.2% (31/303), > 3.25: 13.4% (11/82). Baseline eGFR values [OR 0.93(95%CI 0.90–0.96)], cirrhosis [OR 2.31(95%CI 1.09–4.88)], hypertension [OR 2.36 (95%CI 1.14–4.88)], and albumin [OR 0.31(95%CI 0.14–0.72)] were associated with CKD occurrence. Baseline eGFR values [OR 0.90 (95%CI 0.88–0.93)], hypertension at baseline [OR 2.01(95%CI 1.06–3.81)] and progression to cirrhosis [OR 4.50(95%CI 1.96–10.30)] were related to CKD incidence in non-cirrhotic patients. In the absence of comorbidities, maintaining treatment response after follow-up showed 0.9% of de novo CKD (vs. 8%). Conclusions One of every ten PBC patients showed CKD, mainly related to metabolic factors (hypertension and diabetes), and advanced liver disease (albumin and platelets), increasing the risk of mortality. These conditions were also related to the CKD occurrence, even in non-cirrhotic patients.
- 22 June 2026
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 61 (9) , 1-10
Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis
Background Primary biliary cholangitis (PBC) is a liver disease frequently associated with extrahepatic manifestations. Although a relationship with kidney dysfunction has been reported, data about PBC and chronic kidney disease (CKD) are limited. We assessed the prevalence and incidence of CKD and identify associated risk factors in patients with PBC. Methods This was a multicenter retrospective study involving 1058 consecutive PBC patients. The presence of metabolic comorbidities, including diabetes, hypertension, and dyslipidemia was collected. CKD was defined as eGFR < 60 mL/min/1.73 m2. Results Baseline CKD was found in 10% of patients. The number of metabolic factors was associated with progressively lower eGFR levels and higher rates of CKD. Hypertension[OR 2.77 (95%CI 1.60–4.82)], diabetes[OR 2.17(95%CI 1.13–4.18)], ALT[OR 0.92(95%CI 0.88–0.96)], albumin[OR 0.24(95%CI 0.13–0.43)], and platelets[OR 0.996(95%CI 0.992–0.999)] were associated with baseline CKD. CKD was associated with higher mortality (32.1% vs. 7.3%). Seven percent of patients developed CKD. Baseline FIB-4 was associated with CKD incidence: < 1.45: 3% (13/428), 1.45–3.25: 10.2% (31/303), > 3.25: 13.4% (11/82). Baseline eGFR values [OR 0.93(95%CI 0.90–0.96)], cirrhosis [OR 2.31(95%CI 1.09–4.88)], hypertension [OR 2.36 (95%CI 1.14–4.88)], and albumin [OR 0.31(95%CI 0.14–0.72)] were associated with CKD occurrence. Baseline eGFR values [OR 0.90 (95%CI 0.88–0.93)], hypertension at baseline [OR 2.01(95%CI 1.06–3.81)] and progression to cirrhosis [OR 4.50(95%CI 1.96–10.30)] were related to CKD incidence in non-cirrhotic patients. In the absence of comorbidities, maintaining treatment response after follow-up showed 0.9% of de novo CKD (vs. 8%). Conclusions One of every ten PBC patients showed CKD, mainly related to metabolic factors (hypertension and diabetes), and advanced liver disease (albumin and platelets), increasing the risk of mortality. These conditions were also related to the CKD occurrence, even in non-cirrhotic patients.
- 14 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70639
REACT Score, a Novel Scoring System, Improves the Prediction of Non‐Elective Readmissions in Patients With Decompensated Cirrhosis
Background and Aim: One third of patients with cirrhosis experience an early readmission, and predicting such an event is challenging. We developed and validated a scoring system to predict non‐elective readmissions in patients with cirrhosis. Methods: An observational and multicenter retrospective study enrolled 1382 consecutive non electively admitted patients with cirrhosis and acute decompensation from 20 centers in Spain and were categorized as derivation and validation cohorts. The cohorts were followed for 90 days after discharge. Results: The rate of 7‐day, 30‐day and 90‐day readmission was 5.3%, 19.9% and 36.7%, respectively, while 12.3% of patients died during the study. History of decompensation [HR 1.31 (95% CI 1.04–1.64); p = 0.022], Charlson index [HR 1.08 (95% CI 1.02–1.14); p = 0.012], large‐volume paracentesis [HR 1.37 (95% CI 1.09–1.73); p = 0.007], INR [HR 1.52 (95% CI 1.17–1.97); p = 0.001] and bilirubin [HR 1.03 (95% CI 1.001–1.05); p = 0.045] at prior discharge were associated with early readmission. REACT score distinguished patients at high versus low risk of readmission: (a) derivation cohort 19.6% vs. 0% for 7‐day, 70.6% vs. 2.5% for 30‐day, 91.1% vs. 20.2% for 90‐day; (b) internal validation 20.6% vs. 0% for 7‐day, 58.8% vs. 0.5% for 30‐day, 72.1% vs. 11.8% for 90‐day; (c) external validation 5.8% vs. 0% for 7‐day, 24.6% vs. 0% for 30‐day, 44.2% vs. 12% for 90‐day. Also, high‐risk patients were more likely to be readmitted before their scheduled follow‐up appointment (51.9% vs. 5.7%). Conclusions: Cirrhosis readmission rate was 20% within the first 30 days after discharge. REACT score effectively predicted the risk of non‐elective readmission in patients with decompensated cirrhosis. Prospective studies are needed to fully assess the usefulness of this scoring system in predicting non‐elective readmissions and in developing strategies to prevent them.
- 14 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70639
REACT Score, a Novel Scoring System, Improves the Prediction of Non‐Elective Readmissions in Patients With Decompensated Cirrhosis
Background and Aim: One third of patients with cirrhosis experience an early readmission, and predicting such an event is challenging. We developed and validated a scoring system to predict non‐elective readmissions in patients with cirrhosis. Methods: An observational and multicenter retrospective study enrolled 1382 consecutive non electively admitted patients with cirrhosis and acute decompensation from 20 centers in Spain and were categorized as derivation and validation cohorts. The cohorts were followed for 90 days after discharge. Results: The rate of 7‐day, 30‐day and 90‐day readmission was 5.3%, 19.9% and 36.7%, respectively, while 12.3% of patients died during the study. History of decompensation [HR 1.31 (95% CI 1.04–1.64); p = 0.022], Charlson index [HR 1.08 (95% CI 1.02–1.14); p = 0.012], large‐volume paracentesis [HR 1.37 (95% CI 1.09–1.73); p = 0.007], INR [HR 1.52 (95% CI 1.17–1.97); p = 0.001] and bilirubin [HR 1.03 (95% CI 1.001–1.05); p = 0.045] at prior discharge were associated with early readmission. REACT score distinguished patients at high versus low risk of readmission: (a) derivation cohort 19.6% vs. 0% for 7‐day, 70.6% vs. 2.5% for 30‐day, 91.1% vs. 20.2% for 90‐day; (b) internal validation 20.6% vs. 0% for 7‐day, 58.8% vs. 0.5% for 30‐day, 72.1% vs. 11.8% for 90‐day; (c) external validation 5.8% vs. 0% for 7‐day, 24.6% vs. 0% for 30‐day, 44.2% vs. 12% for 90‐day. Also, high‐risk patients were more likely to be readmitted before their scheduled follow‐up appointment (51.9% vs. 5.7%). Conclusions: Cirrhosis readmission rate was 20% within the first 30 days after discharge. REACT score effectively predicted the risk of non‐elective readmission in patients with decompensated cirrhosis. Prospective studies are needed to fully assess the usefulness of this scoring system in predicting non‐elective readmissions and in developing strategies to prevent them.
- 2 September 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (4) , 1044-1054
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction–associated Steatotic Liver Disease in Clinical Practice
- 2 September 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (4) , 1044-1054
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction–associated Steatotic Liver Disease in Clinical Practice
- Open Access
- 29 April 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (5) , e1787
Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults
Background.: Adult solid organ transplant recipients (SOTRs) have decreased responsiveness to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccination and higher incidence of infection, but there are few data on the serological response in pediatric SOTR. The aim of this study was to determine serological response to SARS-CoV-2 vaccination in pediatric liver (LT) and kidney transplant (KT) recipients and compare it with adult SOTR. Methods.: A European, prospective, multicenter study was performed. Samples were taken at 7 and 32 wk following COVID-19 vaccination and serological endpoints were measured by ELISA. Results.: A total of 42 pediatric (16 post-LT and 26 post-KT) and 117 adult (all post-LT) were included. All pediatric participants and 94% adult participants received mRNA vaccines. Paediatric SOTR patients had significantly higher anti-Spike IgG levels than adult participants at week 7 (114 220.7 [59 285.92–220 058.55] versus 8756.7 [5643.69–13 586.71], P < 0.0001) and week 32 (46 113.2 [10 992.91–193 436.14] versus 8207.0 [3561.20–18 913.43], P = 0.0032). No significant difference in week 7 anti-Spike IgG response was found between pediatric LT and KT (129 434.4 [51 888.64–322 869.69] versus 105 304.5 [39 910.20–277 849.50], P = 0.9854). No differences were seen between children and adults in the rate of decline of anti-Spike IgG between weeks 7 and 32 (P = 0.8000). Male sex and hemolytic-uremic syndrome or postischemic kidney disease were associated with lower anti-Spike IgG levels at week 7 in pediatric SOTR. Conclusions.: Paediatric SOTR demonstrate greater SARS-CoV-2 vaccine responses than comparable adult SOTR patients. These data support efficacy and safety of SARS-CoV-2 vaccination in child SOTR and may alleviate vaccine hesitancy in this patient group.
- 29 April 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (5) , e1787
Open AccessPediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults
Background.: Adult solid organ transplant recipients (SOTRs) have decreased responsiveness to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccination and higher incidence of infection, but there are few data on the serological response in pediatric SOTR. The aim of this study was to determine serological response to SARS-CoV-2 vaccination in pediatric liver (LT) and kidney transplant (KT) recipients and compare it with adult SOTR. Methods.: A European, prospective, multicenter study was performed. Samples were taken at 7 and 32 wk following COVID-19 vaccination and serological endpoints were measured by ELISA. Results.: A total of 42 pediatric (16 post-LT and 26 post-KT) and 117 adult (all post-LT) were included. All pediatric participants and 94% adult participants received mRNA vaccines. Paediatric SOTR patients had significantly higher anti-Spike IgG levels than adult participants at week 7 (114 220.7 [59 285.92–220 058.55] versus 8756.7 [5643.69–13 586.71], P < 0.0001) and week 32 (46 113.2 [10 992.91–193 436.14] versus 8207.0 [3561.20–18 913.43], P = 0.0032). No significant difference in week 7 anti-Spike IgG response was found between pediatric LT and KT (129 434.4 [51 888.64–322 869.69] versus 105 304.5 [39 910.20–277 849.50], P = 0.9854). No differences were seen between children and adults in the rate of decline of anti-Spike IgG between weeks 7 and 32 (P = 0.8000). Male sex and hemolytic-uremic syndrome or postischemic kidney disease were associated with lower anti-Spike IgG levels at week 7 in pediatric SOTR. Conclusions.: Paediatric SOTR demonstrate greater SARS-CoV-2 vaccine responses than comparable adult SOTR patients. These data support efficacy and safety of SARS-CoV-2 vaccination in child SOTR and may alleviate vaccine hesitancy in this patient group.
- 6 March 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (3) , 652-661
Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C
- 6 March 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (3) , 652-661
Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C
- Open Access
- 29 November 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (1) , 101740
Brain reserve in hepatic encephalopathy: Pathways of damage and preventive strategies through lifestyle and therapeutic interventions
- 29 November 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (1) , 101740
Open AccessBrain reserve in hepatic encephalopathy: Pathways of damage and preventive strategies through lifestyle and therapeutic interventions
- 26 September 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , E12-E16
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
- 26 September 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , E12-E16
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
- 24 September 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (2) , 443-449
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.
- 24 September 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (2) , 443-449
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.